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Abstract
Background: In general, inflammation plays a role in most bladder pathologies and represents a defense
reaction to injury that often times is two edged. In particular, bladder neurogenic inflammation involves
the participation of mast cells and sensory nerves. Increased mast cell numbers and tryptase release
represent one of the prevalent etiologic theories for interstitial cystitis and other urinary bladder
inflammatory conditions. The activity of mast cell-derived tryptase as well as thrombin is significantly
increased during inflammation. Those enzymes activate specific G-protein coupled proteinase-activated
receptors (PAR)s.
Four PARs have been cloned so far, and not only are all four receptors highly expressed in different cell
types of the mouse urinary bladder, but their expression is altered during experimental bladder
inflammation. We hypothesize that PARs may link mast cell-derived proteases to bladder inflammation
and, therefore, play a fundamental role in the pathogenesis of cystitis.
Results: Here, we demonstrate that in addition to the mouse urinary bladder, all four PA receptors are
also expressed in the J82 human urothelial cell line. Intravesical administration of PAR-activating peptides
in mice leads to an inflammatory reaction characterized by edema and granulocyte infiltration. Moreover,
the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli
lipopolysaccharide (LPS), substance P, and antigen was strongly attenuated by PAR1-, and to a lesser
extent, by PAR2-deficiency.
Conclusion: Our results reveal an overriding participation of PAR1 in bladder inflammation, provide a
working model for the involvement of downstream signaling, and evoke testable hypotheses regarding the
role of PARs in bladder inflammation. It remains to be determined whether or not mechanisms targeting
PAR1 gene silencing or PAR1 blockade will ameliorate the clinical manifestations of cystitis.
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Background
In general, inflammation plays a role in most bladder
pathologies, including bladder cancer [1-4] and repre-
sents a defensive reaction to injury caused by physical
damage, chemical substances, micro-organisms, or other
agents [1,2]. In particular, bladder neurogenic inflamma-
tion involves the participation of mast cells and sensory
nerves. Evidence for a role of mast cells in cystitis was
reviewed recently [5] and includes the presence of mast
cells containing tryptase in the bladder [6] and urine of IC
patients [6,7], and that mast cell counts in IC patients are
one of the few features significantly associated with night-
time frequency of urination [8]. We have previously pre-
sented direct evidence indicating a key role for mast cells
and their products in bladder inflammation [9-11], and
others emphasized the role of mast cell products in blad-
der disorders [12-14].
As a consequence of inflammation, products of mast cell
degranulation, such as tryptase, can be found in the urine
of cystitis patients [15]. In addition to tryptase, other ser-
ine proteases such as thrombin and trypsin are produced
during tissue damage and make important contributions
to tissue responses to injury, repair, cell survival, inflam-
mation [16-19], and pain [20-24]. Tissue responses to
these enzymes are modulated by protease-activated recep-
tors (PARs), a unique class of G protein-coupled receptors
that use a fascinating mechanism to convert an extracellu-
lar proteolytic cleavage event into a trans-membrane sig-
nal. These receptors carry their own ligands, which remain
cryptic until unmasked by receptor cleavage (for a review,
please see references [20,23,25,26]).
Four PARs have been cloned so far, and all four PARs are
co-expressed in the mouse bladder urothelium [27], with
PAR2 and PAR3 being the most abundant in the bladder
epithelial layer. Although information regarding the pres-
ence of PARs in human urothelial cells is scanty, indirect
evidence indicates that human cancer urothelial cells,
such as J82, augment the conversion of prothrombin to
thrombin, a key activator of PARs [28]. In addition,
thrombin and other elements of the coagulation cascade
activate J82 carcinoma cells, inducing Ca2+ mobilization,
phospholipase C activity, and cell migration [29].
Another human bladder cell line, RT4, responds to
thrombin, tryptase or PAR-APs with an increase in intrac-
ellular phospholipase A2 activity, arachidonic acid and
prostaglandin E2 release [30]. In this work, we determined
whether all four receptors are present in the human
urothelial J82 cell line.
In addition to the urothelium, PAR1 and PAR2 are also
expressed in mouse detrusor muscle, and PAR4 is
expressed in mouse peripheral nerves and plexus cell bod-
ies [27]. Similarly, in rats PAR2, 3, and 4 are expressed in
urothelium, detrusor muscle, and bladder nerve fibers,
and bladder afferent cells in dorsal root ganglia express
PAR2 to 4 [31]. Confocal microscopy has revealed the co-
localization of PAR2, 3, and 4 with protein gene products
9.5 and vanilloid receptor 1, suggesting that PARs are dis-
tributed in C-fiber bladder nerves [31]. In addition, PARs
are differentially modulated during mouse bladder
inflammation. Urothelial PAR2 and, to a lesser extent,
PAR1 are down-regulated in acute inflammation whereas
PAR3 and PAR4 are up-regulated [27]. Bladder fibroblasts
were found to present a clear demarcation in PAR expres-
sion in response to acute and chronic inflammation [27].
Additional evidence for the participation of PARs in the
bladder inflammatory response was the finding that
known pro-inflammatory stimuli such as LPS, substance
P, and antigen challenge induce an increase in PAR4 RNA
within four hours [32]. Upregulation of PAR protein lev-
els have been shown to be part of rat bladder responses to
cyclophosphamide [31].
In order to better understand the role of PARs in cystitis,
we used a well-established mouse model [1,2,26] to deter-
mine the relative potency of PAR-activating peptides
(PAR-APs). PAR3-AP was not included in this research
because of a lack of specificity of the available reagent.
Comparison of inflammatory responses in wild type,
PAR1- and PAR2-deficient mice, revealed a mandatory
role of PAR1 and, to a lesser extent, PAR2 in mediating
bladder responses to a variety of pro-inflammatory stim-
uli.
The combination of morphological results reveals an
overriding participation of PAR1 receptors in bladder
inflammation and provides a working model to investi-
gate the inflammatory cascade downstream of PAR activa-
tion.
Results
Human urothelial cell line expresses all four PARs
In order to extend our previous results obtained with the
mouse bladder [27], we also tested the presence of PA
receptors in the J82 human urothelial cancer cell line. Our
results indicate all four PARs are detectable at the protein
level by immunohistochemistry (Figure 1A–E) and at the
message level by polymerase chain reaction (Figure 2A–B)
in human urothelial cancer cell line.
PAR-APs induce bladder inflammation
Next, we determined whether activation of PARs in mice
would induce bladder inflammation. Figure 3 shows a
representative photomicrograph demonstrating that an
inflammatory response was mounted twenty-four hours
after bladder instillation with PAR4-AP (10 μM). Inflam-
mation secondary to PAR4-AP was characterized by
vasodilation (Figure 4A), sub-epithelial infiltration ofBMC Physiology 2007, 7:4 http://www.biomedcentral.com/1472-6793/7/4
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A-E. PAR immunohistochemistry in J82 human urothelial carcinoma cell line Figure 1
A-E. PAR immunohistochemistry in J82 human urothelial carcinoma cell line. Representative photomicrograph obtained in J82 
cell line stained with PAR specific antibodies. J82 cells were fixed and incubated with primary polyclonal (Santa Cruz Biotech-
nology, Santa Cruz, CA) antibodies: A = PAR-1 (1:20), B = PAR-2 (1:100), C = PAR-3 (1:5), and D = PAR-4 (1:50). Slides were 
washed and incubated with biotinylated secondary antibodies (Vector Labs), goat anti-rabbit (polyclonal antibodies). Orange 
dotted circles highlight some cells considered positives for the particular receptor. Original magnification was ×200. Figure 1E 
represents the average and SEM of number of PAR-positive cells as percent of the total cells per field.
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inflammatory cells (Figure 4B), and edema (Figure 4C). A
high magnification photomicrograph (Figure 4D) indi-
cates that the majority of inflammatory cells responding
to PAR4-AP were polymorphonuclear [PMNs] leukocytes
characteristic of acute bladder inflammation [32]. In addi-
tion, the cellular infiltrate expanded from submucosal lay-
ers towards the detrusor smooth muscle (green arrows in
figure 3A) and within the detrusor nerve elements, previ-
ously shown to contain PAR4 (figure 9 of the reference
[27]), are surrounded by inflammatory cells. Similar
A-B. Polymerase Chain Reaction for detection of PARs message in J82 human urothelial carcinoma cell line Figure 2
A-B. Polymerase Chain Reaction for detection of PARs message in J82 human urothelial carcinoma cell line. Figure 2A is a pho-
tomicrograph of the gel and Figure 2B represents the area under the curve as quantified using Image J software [74]. Primers 
used in this experiment are described in additional file 1 (Table 1).
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results were obtained 48 hours after bladder instillation
with PAR4-AP with the addition of macrophages to the
lesion (data not shown).
Next, we compared the effect of 10 μM concentrations of
PAR1-AP, PAR2-AP, and PAR-4-AP on the degree of PMN
infiltration into the urinary bladder. The representative
photomicrographs on figure 4 indicate that contrast to the
control peptide which failed to induce bladder inflamma-
tion (Figure 5A), PAR1- (Figure 5B), PAR2- (Figure 5C),
and PAR4-AP (Figure 5D) induced different densities of
inflammatory cell infiltrate. Figure 6 summarizes the
results obtained with different concentrations of PAR-APs.
An inflammatory cell infiltrate was detected at concentra-
tions as low as 0.1 μM and reached a peak at 10 μM PAR4-
AP. These results indicate that, at least in the mouse blad-
der, the instillation of 10 μM PAR4-AP or 100 μM PAR1-
AP induces a strong inflammatory reaction characterized
by the highest number of PMNs infiltrating the bladder.
Both PAR1-AP and PAR2-AP at 10 μM concentration
induced bladder inflammation but the number of PMNs
that infiltrated the urinary bladder was smaller than that
observed with PAR4- AP (10 μM). No inflammation was
observed in mice instilled with pyrogen-free saline or 10
μM control peptide dissolved in PBS.
PAR1-/- and PAR2-/- mice were used to determine whether
those receptors were downstream of a common inflam-
matory cascade. We chose the following classical inflam-
matory stimuli: substance P, LPS, and antigen-challenge
(in sensitized mice) because they were shown to depend
on mast cells for eliciting bladder inflammation [7,8,27],
and products of mast cell degranulation such as chymase
and tryptase activate PAR1 [33,34] and PAR2 receptors
[35,36], respectively. For this purpose, groups of anesthe-
tized female, wild type (C57BL/6J), PAR1-/-, and PAR2-/-
mice (n = 6–8) were instilled with saline, or with control
inactive peptide (10 μM), or one of the following sub-
stances at concentrations known to induce inflammatory
response [32]: substance P (10 μM), Escherichia coli LPS
strain 055:B5 (100 μg/ml), DNP4-OVA (in sensitized
mice; 1 μg/ml), PAR1-AP (10 μM), and PAR2-AP (10 μM).
Twenty-four hours later, bladders were removed for quan-
tification of PMN infiltration. Figures 7A and 7B summa-
rize the results obtained. PAR1-/- mice presented a reduced
response to substance P, LPS, and antigen stimulation
(Figure 7A). However, the responses to PAR2-AP obtained
in PAR1-/- mice were not altered (Figure 7B). The major
difference between PAR1-/- and PAR2-/- mice is that the lat-
ter still presented an inflammatory response to antigen
(Figure 7A).
Regarding other inflammatory cells, bladders isolated
from PAR1-/- and PAR2-/- presented equivalent number of
mast cells when compared to wild type mice (mast cell/
cross section: PAR1-/- = 9.7 ± 1.1; PAR2-/- = 11.7 ± 1.9; wild
type = 8.3 ± 0.6 ; p values = 0.30 when comparing WT to
PAR1-/- and p= 0.10 when comparing WT to PAR2-/- ani-
mals). After stimulation with the pro-inflammatory stim-
uli, the bladder of wild type mice presented signs of mast
cell activation by the presence of degranulation. In con-
trast, except for some perivascular infiltrate, few inflam-
matory cells were seen in the bladder of PAR1-/- mice in
response to pro-inflammatory stimuli (data not shown).
In addition, when mast cells were visible, there was no
apparent sign of degranulation, which may reflect poor
activation of those cells (data not shown).
These results indicate that PAR1 receptors are essential for
bladder inflammation secondary to several pro-inflam-
matory stimuli, while PAR-2 receptors seem to have a
decreased role, at least in mediating the responses to anti-
gen challenge. Because the transgenic mouse models used
have been reported to be complete knockouts [18,37-42]
and PAR2-AP has no effect on PAR2 knockout mice
[43,44], we did not test PAR1-AP in PAR1-/-and PAR2-AP
in PAR2 -/- mice.
Discussion
Role of PAR in bladder inflammation
Proteases that are released during inflammation and
injury cleave PARs on the urothelium, detrusor muscle,
and nerve elements to cause neurogenic bladder inflam-
mation [45,46] and hyperalgesia [21,23]. As we demon-
strated earlier by IHC, PARs are over-expressed in the
bladder following cystitis induced by classical mediators
such as LPS and SP [27].
This study determined whether all four PAR receptors are
expressed in human urothelial cell line. The presence of
multiple PARs on the same cell is thought to extend the
range of proteases a cell responds to rather than expand
the range of intracellular responses [30]. Human transi-
tional-cell carcinoma (J82) cells express various G pro-
tein-coupled receptors, and the presence of PARs in this
cell line was based on the effects of thrombin, which
induces a strong migration of J82 cells by a mechanism
that involves Ca2+ mobilization and activation of Rho
kinase leading to a reorganization of the cytoskeleton
[29]. In addition to the J82 cell line, expression of PARs in
RT4 bladder papilloma cells was inferred based on find-
ings that RT4 cells respond to activators of PARs such as
thrombin, tryptase, and PAR-activating peptides[30].
Those PAR activators induced a calcium independent
phospholipase A2 with the consequent release of arachi-
donic acid and synthesis of prostaglandin E2 [30]. Since
the presence of PARs in human urothelium was only
based on circumstantial evidence, we determined whether
J82 carcinoma cell line expresses PAR protein and RNA.BMC Physiology 2007, 7:4 http://www.biomedcentral.com/1472-6793/7/4
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Our results demonstrate that the J82 human urothelial
cell line expresses all four PA receptors.
An additional goal of this paper was to determine whether
PA receptors are part of the inflammatory cascade mediat-
ing the response of the urinary bladder to known pro-
inflammatory stimuli. The stimuli were chosen because
we have published evidence that each one of them when
instilled into the mouse bladder produces inflammation:
substance P [47], LPS [48], and antigen challenge of sen-
sitized mice [10,11]. However, the present manuscript did
not determine which endogenous substance is responsi-
ble for activation of PAR receptors, and therefore, the fol-
lowing discussion is based on the literature and not in the
results of this manuscript. The information regarding
endogenous activators of PARs in the mouse bladder is,
unfortunately, scanty. While human connective tissue
mast cells contain the enzymes chymase and tryptase,
mice contain numerous related proteases [49-51]. Mouse
mast cell protease-7 is a tryptase predominantly expressed
in differentiated connective tissue-type mast cells [52].
Mast cell proteases mcpt5 (chymase), mcpt6 and 7 (tryp-
tases) are expressed during the development of the mouse
embryo [49]. However, to the best of our knowledge,
there is no information regarding which particular tryp-
tase is expressed in the mouse bladder and/or upregulated
in this mouse model during inflammation. Although
thrombin is a recognized physiological activator of PAR1
and PAR4, the endogenous enzymes responsible for acti-
vating PAR2 in urinary bladder are not known. Recently,
it was demonstrated that the tissue kallikrein family of
proteinases are able to regulate PAR signaling and may
represent important endogenous regulators PAR1, PAR2,
and PAR4 [53]. The latter are likely to be confirmed in the
urinary tract, since members of the kallikrein family play
a fundamental role in bladder physiology [54].
Administration of PAR peptide agonists into the urinary
bladder of mice elicited an inflammatory reaction charac-
terized by edema and granulocyte infiltration. Interest-
ingly, the inflammatory responses to PAR4-AP peaked at
10 μM and higher concentrations of this peptide (100
μM) failed to produce an additional increase in PMNs
migration, but rather induced a lesser degree of inflamma-
tion. Several possibilities could explain this finding,
including PAR desensitization and endocytosis [55], shed-
ding of these receptors from the cells, as is the case of
PAR1 in endothelial cells exposed to thrombin [56], and
shedding of urothelial cells bearing these receptor, as we
suggested [27]. Although we observed a potent inflamma-
tory response secondary to PAR4-AP, PAR4-/- mice were
not available in our laboratory at the time this project
started. Nevertheless, our results emphasize the impor-
tance of this receptor in cystitis.
In the present work, we determined that PAR1-/- and, to a
lesser extent, PAR2-/- mice present decreased inflamma-
tory responses to pro-inflammatory stimuli. The results
obtained with PAR-deficient mice provide evidence indi-
cating that substances known to stimulate mast cells, such
as SP and antigen, induce a bladder inflammatory reac-
tion that depends on PAR activation. In addition, these
results indicate that toxins such as LPS, known to be
released during bladder infection, also share the same
PAR pathway.
The authors acknowledge the lack of functional data on in
vivo urinary bladder function at this time. In vitro experi-
ments indicate that both trypsin and PAR-2 activating
peptide (SLIGRL-NH(2)) produced a concentration-
dependent contractile response in the rat urinary bladder
preparations. These contractions were abolished by
removal of the urinary bladder mucosa and were signifi-
cantly reduced by the non-steroidal anti-inflammatory
drug indomethacin [57]. The release of prostaglandins by
PAR-2 activators seems to be partly mediated by the phos-
pholipase A2  (iPLA2) [58]. These responses were
enhanced in bladders isolated from cyclophosphamide-
treated rats [45]. The in vitro work confirms the evidence
that PAR activation leads to iPLA2-mediated prostaglan-
din release in human urothelial carcinoma cell line RT4
PAR4-AP induces bladder inflammation Figure 3
PAR4-AP induces bladder inflammation. Anesthetized 
female C57BL6 mice were catheterized, the bladder was 
emptied, and a volume of 200 μl of a solution of PAR4-AP 
(10 μM) was instilled into the urinary bladder. Twenty four 
hours later, bladders were removed, processed for histology, 
and stained with H&E. At low magnification, photomicro-
graph illustrates the distribution of inflammatory cells 
extending from the submucosa to deep regions in the detru-
sor smooth muscle (green arrows). Magnifications = ×100BMC Physiology 2007, 7:4 http://www.biomedcentral.com/1472-6793/7/4
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A-D. PAR4-AP induces bladder inflammation Figure 4
A-D. PAR4-AP induces bladder inflammation. Anesthetized female C57BL6 mice were catheterized, the bladder was 
emptied, and a volume of 200 μl of a solution of PAR4-AP (10 μM) was instilled into the urinary bladder. Twenty four hours 
later, bladders were removed, processed for histology, and stained with H&E. A characteristic photomicrograph represents 
sub-urothelium inflammatory infiltrate around a blood vessel (A) and dilation of blood vessels (white arrow). At higher magni-
fication (B), it was possible to visualize that the majority of inflammatory cells in response to PAR4-AP presented a character-
istic "doughnut" shape indicative of mouse PMNs (green arrowhead). The submucosal edema is illustrated in C. Figure 4D 
illustrates inflammatory cells surrounding a structure  resembling a nerve element (black arrow). Magnifications A = ×200, B = 
×400, C = ×200, and D = ×400.BMC Physiology 2007, 7:4 http://www.biomedcentral.com/1472-6793/7/4
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A-D. Comparison of different PAR-APs in inducing mouse bladder inflammation Figure 5
A-D. Comparison of different PAR-APs in inducing mouse bladder inflammation. Characteristic photomicrographs 
of bladders removed from female C57BL6 mice that received instillation of (A = control peptide; B = PAR1-AP; C = PAR2-AP, 
and D = PAR4-AP). All peptides were at the concentration of 10 μM and bladders were removed 24 hours after challenge. Of 
note, absence of inflammation following instillation with control peptide (A), submucosal PMN infiltrate induced by PAR1-AP 
(B), modest perivascular infiltration in response to PAR2-AP (C), and overwhelming PMN infiltration in response to PAR4-AP 
(D). Magnifications: A, B, C, and D = ×200.BMC Physiology 2007, 7:4 http://www.biomedcentral.com/1472-6793/7/4
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[30], human bladder microvascular endothelial [59,60],
and normal urothelial cells [61]. However, there is no in
vivo functional data on the effect of PAR stimulation on
bladder urodynamic behavior.
It is not clear why the experimental cystitis in PAR2-/- mice
was not totally abolished, as seen in PAR1-/-. Both PAR1 -/
- and PAR2 -/- mice have been well characterized [18,37-
42]; see [62,63] for reviews. In addition, PAR2-AP has no
effect on PAR2 knockout mice [43,44]. Nevertheless, com-
pensatory mechanisms from other PA receptors could be
possible. Regarding the difference of response between
PAR1 -/- and PAR2 -/- mice, this may reflect a different role
of the endogenous ligand since PAR1 is activated by
thrombin, while PAR2 is activated by mast cell tryptase
[23]. It has to be taken into consideration that some of the
PAR agonists, such as thrombin, activate more than one
receptor. Indeed, in addition to PAR1, thrombin activates
PAR4 [20] and type-II TGFβ receptors and consequently
leads to their down regulation [64]. PAR1 [65] and possi-
bly PAR3 and PAR4 are involved in vascular inflamma-
tion, but the primary role for PAR2 seems to be
cytoprotection in the gastro intestinal tract [66,67] and
airways [68]. It was reported that whereas PAR1-/- mice do
Effect of different concentrations of PAR1-, PAR2-, and PAR4-AP on PMNs migration Figure 6
Effect of different concentrations of PAR1-, PAR2-, and PAR4-AP on PMNs migration. Anesthetized female 
C57BL6 mice were catheterized, the bladder was emptied, and a volume of 200 μl of a solution of control peptide (10 μM) or 
PAR1-, PAR2-, and PAR4-AP at different concentrations (0.1 to 1000 μM) was instilled into the urinary bladder. The number of 
PMNs migration into the mouse bladders was examined 24 hours after instillation (n = 8 for PAR4-AP and control peptide and 
n = 4 for PAR1-AP and PAR2-AP).
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A-B. Comparison of the inflammatory responses (PMNs infiltration) obtained with wild type (C57BL/6J), PAR1-/-, and PAR2-/-  mice Figure 7
A-B. Comparison of the inflammatory responses (PMNs infiltration) obtained with wild type (C57BL/6J), PAR1-/-, and PAR2-/- 
mice. Responses were obtained 24 hours after bladder instillation with one of the listed substances. Figure 7A represents the 
response to substance P (10μM), Escherichia coli LPS strain 055:B5 (100 μg/ml), and DNP4-OVA (in sensitized mice; 1 μg/ml) 
compared to saline (black bars). Figure 7B represents the responses to PAR1-AP (10 μM) and PAR2-AP (10 μM) compared 
to control inactive peptide (10 μM). Number of mice = 6–8 per group. NS= not significant. Asterisks represent a statistically 
significant difference (p < 0.05) between the responses obtained with each pro-inflammatory stimuli in PAR1-/- or PAR2-/- and 
the respective response obtained in wild type mice.
W T PAR1 KO PAR2 KO
0
2
4
6
8
CTRL PEPT
PAR2-AP
PAR1-AP
B
P
N
M
S
/
A
r
e
a
 
(
m
i
c
r
o
n
s
)
2
 
x
1
0
WT PAR1 KO PAR2 KO
N
O
T
 
D
O
N
E
N
O
T
 
D
O
N
E
W T PAR1 KO PAR2 KO
0
2
4
6
8
SALINE
LPS
ANTIGEN
SP
A
NS
*
*
*
*
*
P
N
M
S
/
A
r
e
a
 
(
m
i
c
r
o
n
s
)
2
 
x
1
0
WT PAR1 KO PAR2 KOBMC Physiology 2007, 7:4 http://www.biomedcentral.com/1472-6793/7/4
Page 11 of 15
(page number not for citation purposes)
not mount inflammatory responses to a variety of stimuli,
PAR2-/- mice present a delayed microvascular inflamma-
tion [40] and a reduced encephalomyelitis [69].
Another possible explanation for the discrepancy between
PAR1 and PAR2 is the differential localization of the two
PARs in urinary bladder. PAR2 is much more abundant
than PAR1 in the urothelium. However, following acute
and chronic inflammation, probably because of the shed-
ding of urothelial cells bearing PARs, both PAR1 and
PAR2 expression are reduced [24]. Alternatively, the asso-
ciation between PAR1 and PAR2 with vallinoid receptors
[70] in sensory C fibers deserves further investigation as a
possible explanation for a differential participation of
PAR1 and PAR2 in inflammation. Another hypothesis
points to the control of PAR by a metalloproteinase-
dependent shedding of proteins from the cell surface [56].
More recently, it has been shown in humans that the
downstream signal transduction cascade in response to
PAR2 but not PAR1 depends on an interacting partner, the
Jun activation domain-binding protein 1 (Jab1) [71].
Taken together, data from literature suggests a differential
fate for PAR1 receptor as compared to PAR2 receptor,
which could help to explain the difference in response to
inflammatory stimuli in the bladder of PAR1-/- versus
PAR2-/- mice. Regardless of the receptor type, our findings
demonstrate an overwhelming participation of PARs in
bladder inflammation and place them in a central role
controlling the communication between the immune sys-
tem represented by mast cells, the sensory system repre-
sented by SP, and infection represented by LPS.
Conclusion
This work indicates an overriding participation of PAR1
receptors in bladder inflammation, provides a working
model for the involvement of a network of transcripts
downstream of PAR1 activation, and evokes testable
hypotheses regarding the regulation of PAR. It remains to
be determined whether PAR1 receptor blockade or selec-
tive gene silencing of transcripts downstream of PAR acti-
vation will ameliorate the clinical manifestation of
cystitis. Inhibiting of PAR up-regulation using small inter-
fering RNA technology, as confirmed by immunoblotting,
should substantially reduced bladder inflammatory
response as it has been shown in other systems [36].
Methods
Human Urothelial Cell Culture
Human bladder carcinoma cell line J82 (HTB-1) were
obtained from the American Tissue Culture Collection.
J82 cells were seeded onto a 4-chambers slide and cul-
tured in Minimum Essential Media (MEM), supple-
mented with 10% fetal bovine serum (FBS), 100 μM non-
essential amino acids, 1 mM sodium pyruvate, 100 U/ml
penicillin/streptomycin and 2 × MEM Vitamin Solution.
Cells were maintained at 37°C in a humidified atmos-
phere containing 5% CO2  until 90% confluence was
reached. The medium was removed and cells were fixed in
10% formalin.
PARs IHC in human cell line
Fixed cells were processed for routine immunohistochem-
istry according to published methods [27]. All reagent
incubations (30 min) and washes were performed at
room temperature. Normal blocking serum (Vector Labs,
Burlingham, CA) was placed on all slides for 10 min and,
after a brief rinse in PBS, sections were incubated with pri-
mary polyclonal (Santa Cruz Biotechnology, Santa Cruz,
CA) antibodies: PAR-1 (1:20), PAR-2 (1:100), PAR-3
(1:5), and PAR-4 (1:50). Slides were washed and incu-
bated with biotinylated secondary antibodies (Vector
Labs), and goat anti-rabbit (polyclonal antibodies). After
rinsing in PBS, the avidin-biotin-horseradish peroxidase
complex reagent (ABC-HRP, Vector Labs) was added.
Slides were washed and treated with the chromogen 3,3'-
diaminobenzidine (DAB, Biomeda, Foster City, CA) (two
changes, 5 min each), rinsed in dH20, counterstained with
hematoxylin, dehydrated, and coverslipped with Per-
mount (Fisher Scientific) mounting media. Positive cells
were visualized by microscope (Eclipse E600, Nikon,
Lewisville, TX). All tissues were photographed at room
temperature by a digital camera (DXM1200; Nikon). Five
random fields per slide were counted. Images were ana-
lyzed with Image-Pro Analyzer® (Media Cybernetics Inc.;
Silver Spring, MD). The number of positive cells per field
at 200 × magnification was calculated as percent of the
total cells (200 × magnification). Results are presented as
average and standard error of the mean.
PARs Polymerase chain reaction assay (PCR) in human cell 
line
Total RNA was extracted in Ultraspec RNA solution (Bio-
tecx Laboratories Inc. Houston, TX) according to the man-
ufacturer's instructions. The amount and quality of the
RNA were verified by measuring the absorbance at 260
and 280 nm, and by electrophoresing the samples on a
formaldehyde/agarose gel. Oligo(dT)-primed reverse
transcription of RNA was performed with the SuperScript
First-Strand Synthesis System for reverse transcriptase-
polymerase chain reaction (RT-PCR) (Invitrogen,
Carlsbad, CA), using 5 μg of RNA for each reaction. Fol-
lowing reverse transcription, PCR amplifications were per-
formed from 2 μl of each cDNA. Primer pairs were
designed using Primer 3 [72]. Details of the primer
sequences are given in additional file 1 (Table 1) and were
designed according to reference [73]. The designed prim-
ers shared 100% homology with the target sequence but
no significant homology with other sequences.BMC Physiology 2007, 7:4 http://www.biomedcentral.com/1472-6793/7/4
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The PCR program consisted of one preincubation at 94°C
for 2 min and 40 cycles at 94°C for 30 s, 55°C for 30 s
(50°C for 1 min for PAR1), 68°C for 1 min (3 min for
PAR1), and 68°C for 5 min. All PCR reactions were per-
formed with a Robocycler Gradient 96 with a heated lid
(Stratagene, La Jolla, CA) in 50 μl of 1 × PCR buffer, 1.5
mM MgCl2, forward and reverse primers at 0.2 μM, 200
μM dNTP, and 1 U of Taq DNA polymerase (Invitrogen).
Twenty microliters of the amplification mixtures were
analyzed by agarose gel electrophoresis. Beta-actin was
used as positive control. Images of the PCR products were
taken using the FluorChem HD digital darkroom (Alpha
Innotech, San Leandro, CA) and the area under the curve
was quantified using Image J software [74].
Animals
All animal experimentation described here was performed
in conformity with the "Guiding Principles for Research
Involving Animals and Human Beings (OUHSC Animal
Care & Use Committee protocol #05-088I). PAR1-/-[38],
PAR2-/-  [75], and C57BL/6J mice were used in this
research. C57BL/6J mice were used as wild type since
PAR1-/- and PAR2-/- were enriched in this background.
Antigen sensitization protocol
One group of mice was sensitized with 1 μg DNP4-human
serum albumin (HSA) in 1 mg alum on days 0, 7, 14, and
21, intraperitoneally (i.p.). This protocol induces sus-
tained levels of IgE antibodies up to 56 days post-sensiti-
zation [76]. One week after the last sensitization, cystitis
was induced as described below.
Induction of cystitis
Acute cystitis was induced in 8 mice per group, as
described previously [27,32,48,77,78]. Briefly, female
wild type (C57BL/6J), PAR1-/-, and PAR2-/- mice were
anesthetized (ketamine 200 mg/kg and xylazine 2.5 mg/
kg, i.p.), then transurethrally catheterized (24 Ga.; 3/4 in;
Angiocath, Becton Dickson, Sandy, Utah), and the urine
was drained by applying slight digital pressure to the
lower abdomen. The urinary bladders were instilled with
200 μl of one of the following substances: pyrogen-free
saline, SP (10 μM), Escherichia coli LPS strain 055:B5
(Sigma, St. Louis, MO; 100 μg/ml), antigen (in sensitized
mice; DNP4-OVA 1 μg/ml), control inactive peptide
(LRGILS [55]), or PAR- activating peptides (PAR1-AP =
SFFLRN [55]; PAR2-AP = SLIGRL [55]; and PAR4-AP =
AYPGKF [79]). Substances were infused at a slow rate to
avoid trauma and vesicoureteral reflux (18). To ensure
consistent contact of substances with the bladder, infu-
sion was repeated twice within a 30-min interval and a 1-
ml TB syringe was kept on the catheter end to retain the
intravesical solution for at least for 1 hour. The catheter
was removed, and mice were allowed to void normally.
Twenty-four hours after instillation, mice were euthanized
with pentobarbital (200 mg/kg, i.p.), and the bladders
were removed rapidly.
Quantification of inflammation
H&E stained sections were visualized under microscope
(Eclipse E600, Nikon, Lewisville, TX). All tissues were
photographed at room temperature by a digital camera
(DXM1200; Nikon). Exposure times were held constant
when acquiring images from different groups. Images
were analyzed with Image-Pro Analyzer® (Media Cyber-
netics Inc.; Silver Spring, MD 20910). The number of pol-
ymorphonuclear [PMNs] leukocytes was counted in a
blinded fashion in 10 random fields per slide in two non-
consecutive sections per urinary bladder at 200 × magnifi-
cation. The number of PMNs was normalized per cross-
sectional area (μm2). The number of infiltrate PNMs was
the most reproducible sign of acute bladder inflammation
and, therefore, it was used for quantification.
Statistical Analysis
Data in figures represent the mean ± SEM of the indicated
number of samples. The difference between two mean val-
ues was analyzed with the unpaired Student's t-test. Since
we did not assume equal variance because the variance of
PMN population is unknown, p values were correct using
a Welch's test (GraphPad Prism software version 4.0;
GraphPad Software, Inc. San Diego, CA 92130). A value of
p < 0.05 was considered statistically significant.
Materials
PAR1-AP, PAR2-AP, and PAR4-AP were synthesized at the
Molecular Biology Resource Facility, William K. Warren
Medical Research Institute, OUHSC, as carboxyl-terminal
amides, purified by high-pressure liquid chromatography,
and characterized by mass spectroscopy. Peptide solu-
tions were made fresh in PBS from powder.
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